@Article{,
AUTHOR = {Fred Saad, Kim Chi, Neil Fleshner},
TITLE = {The role of bisphosphonates in the management of bone metastases in prostate cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {11},
YEAR = {2004},
NUMBER = {5},
PAGES = {2376--2382},
URL = {http://www.techscience.com/CJU/v11n5/62574},
ISSN = {1488-5581},
ABSTRACT = {Bone metastases are associated with significant skeletal-related morbidity that negatively correlates with quality
of life and survival in patients with prostate cancer. Once
prostate cancer has metastasized to bone, the median
survival of patients is approximately 30 to 53 months;
therefore, the chronic consequences of bone complications
must be taken into consideration when developing long-term therapeutic strategies in this patient population.
In addition to the bone-damaging effects of metastases,
bone loss related to long-term hormonal therapy, as well
as age-related bone loss, further compromise bone
integrity in patients with advanced prostate cancer.<br/>
This article reviews the burden of skeletal complications
in patients with prostate cancer, and the evidence for
the use of bisphosphonates for the treatment of skeletal
morbidity in this patient population.},
DOI = {}
}